AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

VELA TECHNOLOGIES PLC

Regulatory Filings Sep 25, 2019

8002_rns_2019-09-25_5d208b81-868a-4a75-8265-29469be30e92.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6388N

Vela Technologies PLC

25 September 2019

25 September 2019

Vela Technologies plc

("Vela")

Change of Registered Office

The Board of Vela (AIM: VELA) announces that its registered office address has changed to 15 Victoria Mews, Mill Field Road, Cottingley Business Park, Bingley BD16 1PY.

For further information, please contact: 

Vela Technologies plc Tel: +44 (0) 7802 262 443
Brent Fitzpatrick, Non-Executive Chairman

Antony Laiker, Director
Allenby Capital Limited

(Nominated Adviser)
Tel: +44 (0) 20 3328 5656
Nick Athanas/Asha Chotai
Smaller Company Capital Limited

(Broker)
Tel: +44 (0) 20 3651 2910
Rupert Williams/Jeremy Woodgate

About Vela Technologies 

Vela Technologies (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. There are currently 12 investments in the portfolio which either have developed ways of utilising technology or developing technology with a view to disrupting the businesses or sector in which they operate. More recently, Vela Technologies has also started to focus on existing listed companies where valuations may offer additional opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

CROLLFIIADIEFIA

Talk to a Data Expert

Have a question? We'll get back to you promptly.